Cargando…

Could HBx Protein Expression Affect Signal Pathway Inhibition by Gefitinib or Selumetinib, a MEK Inhibitor, in Hepatocellular Carcinoma Cell Lines?

Hepatitis B virus X (HBx) protein has been known to play an important role in development of hepatocellular carcinoma (HCC). The aim of this study is to find out whether HBx protein expression affects antiproliferative effect of an epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Yoon Kyung, Kim, Kang Mo, Lee, Young-Joo, Kim, Ki-Hun, Lee, Sung-Gyu, Lee, Danbi, Shim, Ju Hyun, Lim, Young-Suk, Lee, Han Chu, Chung, Young-Hwa, Lee, Yung Sang, Suh, Dong Jin
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031005/ https://www.ncbi.nlm.nih.gov/pubmed/21286012 http://dx.doi.org/10.3346/jkms.2011.26.2.214

Ejemplares similares

A simple and clinically applicable model to predict liver-related morbidity after hepatic resection for hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion
por: Lee, Danbi, et al.
Publicado: (2018)

Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma
por: Lee, Joo Young, et al.
Publicado: (2012)

Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
por: An, Jihyun, et al.
Publicado: (2017)

The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection
por: Na, Seong Kyun, et al.
Publicado: (2018)

Chronic hepatitis B infection and non-hepatocellular cancers: A hospital registry-based, case-control study
por: An, Jihyun, et al.
Publicado: (2018)

Alitretinoin Treatment for Gefitinib-Induced Paronychia
por: Lee, Soo Young, et al.
Publicado: (2019)

Identification of hepatic steatosis in living liver donors by machine learning models
por: Lim, Jihye, et al.
Publicado: (2022)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)

Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma
por: Yang, Jee Eun, et al.
Publicado: (2014)

The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment
por: Choi, Jonggi, et al.
Publicado: (2022)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE
por: Lim, Jihye, et al.
Publicado: (2021)

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
por: Prado, C M M, et al.
Publicado: (2012)

No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
por: Heo, Nae-Yun, et al.
Publicado: (2014)

Development of machine learning-based clinical decision support system for hepatocellular carcinoma
por: Choi, Gwang Hyeon, et al.
Publicado: (2020)

3-Deoxysappanchalcone Inhibits Cell Growth of Gefitinib-Resistant Lung Cancer Cells by Simultaneous Targeting of EGFR and MET Kinases
por: Lee, Jin-Young, et al.
Publicado: (2023)

Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer
por: Lee, Kangwook, et al.
Publicado: (2016)

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma
por: Kenney, Cara, et al.
Publicado: (2021)

Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
por: Nakai, Chikako, et al.
Publicado: (2023)

Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center
por: Kim, Sung Eun, et al.
Publicado: (2011)

Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma
por: Lee, Hyo Jeong, et al.
Publicado: (2015)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Huang, Hui-Ju, et al.
Publicado: (2021)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
por: Dymond, Angela W., et al.
Publicado: (2017)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
por: Haslett, K., et al.
Publicado: (2021)

Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib
por: Kim, Hyojeong, et al.
Publicado: (2013)

Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients
por: Jin, Young-Joo, et al.
Publicado: (2012)

Anti-Proliferative Effects of HBX-5 on Progression of Benign Prostatic Hyperplasia
por: Jin, Bo-Ram, et al.
Publicado: (2018)

Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014)

The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo
por: Zou, Yun, et al.
Publicado: (2017)

The Effect of Metformin Treatment on CRBP-I Level and Cancer Development in the Liver of HBx Transgenic Mice
por: Kim, Jo-Heon, et al.
Publicado: (2013)

Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
por: Yoon, Sang Min, et al.
Publicado: (2020)

Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
por: Han, Ji-Youn, et al.
Publicado: (2015)

Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial
por: An, Jihyun, et al.
Publicado: (2017)

Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study
por: Jang, Jeong Yun, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy as an Alternative Treatment for Small Hepatocellular Carcinoma
por: Yoon, Sang Min, et al.
Publicado: (2013)

HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma
por: Oda, Chiyumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b139f25dsf2p5rjdrg9tmdgmmm